Učitavanje...
Why your new cancer biomarker may never work: Recurrent patterns and remarkable diversity in biomarker failures
Less than 1% of published cancer biomarkers actually enter clinical practice. Although best practices for biomarker development are published, optimistic investigators may not appreciate the statistical near-certainty and diverse modes by which the other 99% (likely including your favorite new marke...
Spremljeno u:
| Glavni autor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513583/ https://ncbi.nlm.nih.gov/pubmed/23172309 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-12-3232 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|